Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein(a) levels by more than 90% for at least six months with a single injection in a phase 2 trial, reinforcing its ...

Amgen has reported encouraging mid-stage results for its olpasiran candidate for reducing lipoprotein(a) – a risk factor for atherosclerotic cardiovascular disease – and now plans to move ahead ...

LPUs grant owners a share in the partnership's income, avoiding double taxation. MLPs distribute available cash to unit holders after deducting maintenance capital. Limited partners only risk losing ...

Chart does not reflect overnight price.

Is MPLX a buy now? Chart does not reflect overnight price.

High levels of Lp(a) impact approximately 1 in 5 individuals globally, signaling an elevated risk of heart attacks, strokes, and valve disease. How should clinicians navigate this challenge, given the ...